Analyzing Fresh Tracks Therapeutics (NASDAQ:FRTX) and X4 Pharmaceuticals (NASDAQ:XFOR)
Analyzing Fresh Tracks Therapeutics (NASDAQ:FRTX) and X4 Pharmaceuticals (NASDAQ:XFOR)
Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Rating) and X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
Fresh Track Treeutics(納斯達克：FRTX-GET評級)和X4製藥(納斯達克：XFOR-GET評級)都是小盤醫療公司，但哪一家是優勢投資？我們將根據這兩家公司的股息實力、分析師建議、收益、機構所有權、估值、盈利能力和風險對它們進行比較。
Valuation & Earnings
估值與收益
This table compares Fresh Tracks Therapeutics and X4 Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
此表比較了Fresh Track Treeutics和X4 PharmPharmticals的營收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fresh Tracks Therapeutics | $400,000.00 | 16.24 | -$39.47 million | ($8.39) | -0.27 |
| X4 Pharmaceuticals | $3.00 million | 25.16 | -$88.70 million | ($2.82) | -0.39 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 新奇軌道治療公司 | $400,000.00 | 16.24 | -3,947萬元 | ($8.39) | -0.27 |
| X4製藥公司 | 300萬美元 | 25.16 | -8870萬美元 | ($2.82) | -0.39 |
Fresh Tracks Therapeutics has higher earnings, but lower revenue than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Fresh Tracks Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fresh Track治療公司比X4製藥公司有更高的收益，但收入更低。X4製藥的市盈率低於Fresh Track Treeutics，這表明它目前是兩隻股票中更負擔得起的一隻。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Fresh Tracks Therapeutics | -453.11% | -133.55% | -108.52% |
| X4 Pharmaceuticals | N/A | -184.37% | -92.38% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 新奇軌道治療公司 | -453.11% | -133.55% | -108.52% |
| X4製藥公司 | 不適用 | -184.37% | -92.38% |
Analyst Recommendations
分析師建議
This is a breakdown of current recommendations and price targets for Fresh Tracks Therapeutics and X4 Pharmaceuticals, as reported by MarketBeat.
這是MarketBeat報道的Fresh Track治療公司和X4製藥公司目前的建議和價格目標的細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | N/A |
| X4 Pharmaceuticals | 0 | 0 | 5 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 新奇軌道治療公司 | 0 | 0 | 0 | 0 | 不適用 |
| X4製藥公司 | 0 | 0 | 5 | 0 | 3.00 |
Fresh Tracks Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 76.99%. X4 Pharmaceuticals has a consensus target price of $6.86, indicating a potential upside of 529.10%. Given X4 Pharmaceuticals' higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Fresh Tracks Therapeutics.
Fresh Track治療公司目前的共識目標價為4.00美元，表明潛在上行空間為76.99%。X4 PharmPharmticals的共識目標價為6.86美元，表明潛在上行529.10%。鑑於X4製藥公司更有可能上行，分析師顯然認為X4製藥公司比Fresh Track治療公司更有利。
Institutional and Insider Ownership
機構和內部人持股
7.7% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 56.5% of X4 Pharmaceuticals shares are held by institutional investors. 4.5% of Fresh Tracks Therapeutics shares are held by company insiders. Comparatively, 95.9% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Fresh Track治療公司7.7%的股份由機構投資者持有。相比之下，X4製藥56.5%的股份由機構投資者持有。Fresh Track治療公司4.5%的股份由公司內部人士持有。相比之下，X4製藥95.9%的股份由公司內部人士持有。強大的機構持股表明，對衝基金、捐贈基金和大型基金經理相信，從長期來看，一隻股票的表現將好於大盤。
Volatility and Risk
波動性和風險
Fresh Tracks Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.
Fresh Track治療公司的貝塔係數為0.29，這表明其股價的波動性比標準普爾500指數低71%。相比之下，X4製藥的貝塔係數為0.48，這表明其股價的波動性比標準普爾500指數低52%。
Summary
摘要
X4 Pharmaceuticals beats Fresh Tracks Therapeutics on 10 of the 13 factors compared between the two stocks.
在兩隻股票之間的13個因素中，X4製藥公司在10個因素上擊敗了Fresh Track治療公司。
About Fresh Tracks Therapeutics
關於Fresh Track治療公司
(Get Rating)
(獲取評級)
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Fresh Track治療公司是一家臨牀階段的製藥公司，致力於開發各種處方療法，用於治療美國的自身免疫、炎症和其他令人衰弱的疾病。該公司開發的產品包括：已完成治療原發性腋窩多汗症的第三階段臨牀試驗的索吡溴銨；用於治療自身免疫和炎症性疾病的口服DYRK1A抑制劑BBI-02；以及用於潛在治療自體炎症和罕見遺傳性疾病的幹擾素基因共價刺激物BBI-10，以及下一代激酶抑制劑。它與Carna Biosciences，Inc.，Voronoi Inc.，Bodor實驗室，Inc.和Nicholas S.Bodor博士以及Anges，Inc.簽訂了許可和合作協議。該公司前身為Brickell Biotech，Inc.，並於2022年9月更名為Fresh Track治療公司。Fresh Track治療公司成立於2009年，總部設在科羅拉多州博爾德市。
About X4 Pharmaceuticals
關於X4製藥公司
(Get Rating)
(獲取評級)
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
X4製藥公司是一家生物技術公司，致力於開發治療傳染病的人類抗體。該公司專注於通過開發治療罕見疾病的新療法來恢復健康的免疫系統功能。其正在籌備的產品包括X4P-001、X4P-002和X4P-003。該公司由Henri A.Termeer、Keith T.Flaherty、Renato T.Skerlj、Richard Peters和Paula Ragan於2010年創立，總部位於馬薩諸塞州波士頓。
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受新聞和評級的新軌道治療每日-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對Fresh Track Treeutics和相關公司的評級的每日摘要。